Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


Peter Keen appointed to the Prelude Trust Board


Board Appointment

Prelude Trust plc (“Prelude” or “the Trust”), the investment trust managed by Esprit Capital Management Ltd (“Esprit”) that specialises in high growth technology-based businesses, is pleased to announce that Peter Keen has been appointed to the Board with effect from 1 August 2007.

Peter who is a Partner at Esprit Capital Partners LLP comes to the Board with over 23 years experience in both management and investing in technology and life science businesses. Having trained as a chartered accountant with Arthur Young (now Ernst & Young), he spent 12 years in the healthcare and biotechnology industries with Agricultural Genetics Ltd, Cambridge Life Sciences plc and Chiroscience Group plc. He was a co-founder of Chiroscience having been part of the original venture backed buyout and was responsible for its IPO in 1994. In 1996, he co-founded the life sciences venture capital firm Merlin Biosciences, where he was UK Managing Director until early 2003 and prior to joining Esprit last year he was Chief Financial Officer of Arakis Ltd where he led a refinancing and a successful £106m trade sale, having been responsible at Merlin for the original seed investment.

In 1997 he was involved in the launch of an investment trust the Biotech Growth Trust plc where he remains a non-executive director and he is also a non executive director of Abcam plc and Ark Therapeutics Group plc.

Commenting on the appointment Mike Brooke, Chairman of Prelude said: “I am delighted that Peter is joining our Board, he has been an invaluable member of the Prelude team since joining in November last year. Peter is an asset to the Trust, bringing with him the perfect mix of experience, combining technology and life science venture capital funding, with publicly listed vehicles and an array of financial management roles. I look forward to working alongside Peter and welcome his contribution to the Board.”

Director Declaration

The following information is given in accordance with paragraph 9.6.13 of the Listing Rules:-

Peter Keen is currently a director of the following publicly quoted companies:
Ark Therapeutics plc
Abcam plc
The Biotech Growth Trust plc (Formerly Finsbury Emerging Biotechnology plc)

Peter Keen has held the following directorships in publicly quoted companies in the past five years of which he is no longer a director:
BioProgress plc
ReNeuron Holdings plc

There are no further disclosures to be made pursuant to paragraph 9.6.13 of the Listing Rules.
The Company has been advised that Peter Keen does not have a beneficial interest in shares of the Company.

For further information, please visit or contact:

Peter Keen/Jayne Tamblin John West/Clemmie Carr
Prelude Trust plc Tavistock Communications
Tel: 01223 307 770 Tel: 020 7920 3150


Publisher Contact Information:

Prelude Trust
+44 1223 307 770

Company profile of DFJ Esprit (formerly Prelude Ventures Ltd.)
Past press releases of DFJ Esprit (formerly Prelude Ventures Ltd.).


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Nov 25€24.0MInternet commerce
Feb 21€87.0MInternet services
Feb 21€18.0MInternet commerce
Feb 20€4.3MSoftware development
Feb 19€0.4MInternet commerce
Feb 19€8.4MMedical devices
Feb 18€25.0MBiotechnology

For information on Europe's most extensive database on technology funding click here!


Press Releases

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Jan 29
yumpingo raises $10m to transform guest experiences in restaurants

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.